tbuckley/cabot-search huggingface dataset:
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial
Authors: Floris H B M Schreuder, Koen M van Nieuwenhuizen, Jeannette Hofmeijer, Sarah E Vermeer, Henk Kerkhoff, Elles Zock, Gert-Jan Luijckx, Gert P Messchendorp, Julia van Tuijl, H Paul Bienfait, Suzanne J Booij, Ido R van den Wijngaard, Michel J M Remmers, Antonia H C M L Schreuder, Diederik W Dippel, Julie Staals, Paul J A M Brouwers, Marieke J H Wermer, Jonathan M Coutinho, Vincent I H Kwa, Isabelle C van Gelder, Roger E G Schutgens, Berber Zweedijk, Ale Algra, Jan Willem van Dalen, L Jaap Kappelle, Gabriel J E Rinkel, H Bart van der Worp, Catharina J M Klijn
Journal: The Lancet Neurology (2021)
Increased circulating CRTH2<sup>+</sup>Tregs are associated with asthma control and exacerbation
Authors: Teerapol Chantveerawong, Sasipa Sangkangjanavanich, Chirawat Chiewchalermsri, Panitan Pradubpongsa, Wat Mitthamsiri, Sarawut Jindarat, Ming Wang, Mübeccel Akdis, Milena Sokolowska, Cezmi A. Akdis, Atik Sangasapaviliya, Tadech Boonpiyathad
Journal: Allergy (2021)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Vaccination Coverage by Age 24 Months Among Children Born in 2017 and 2018 — National Immunization Survey-Child, United States, 2018–2020
Authors: Holly A. Hill, David Yankey, Laurie D. Elam-Evans, James A. Singleton, Natalie Sterrett
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Immunization is a safe and cost-effective means of preventing illness in young children and interrupting disease transmission within the community.* The Advisory Committee on Immunization Practices (ACIP) recommends vaccination of children against 14 diseases during the first 24 months of life (1). CDC uses National Immunization Survey-Child (NIS-Child) data to monitor routine coverage with ACIP-recommended vaccines in the United States at the national, regional, state, territorial, and selected local levels.† CDC assessed vaccination coverage by age 24 months among children born in 2017 and 2018, with comparisons to children born in 2015 and 2016. Nationally, coverage was highest for ≥3 doses of poliovirus vaccine (92.7%); ≥3 doses of hepatitis B vaccine (HepB) (91.9%); ≥1 dose of measles, mumps, and rubella vaccine (MMR) (91.6%); and ≥1 dose of varicella vaccine (VAR) (90.9%). Coverage was lowest for ≥2 doses of influenza vaccine (60.6%). Coverage among children born in 2017-2018 was 2.1-4.5 percentage points higher than it was among those born in 2015-2016 for rotavirus vaccine, ≥1 dose of hepatitis A vaccine (HepA), the HepB birth dose, and ≥2 doses of influenza vaccine. Only 1.0% of children had received no vaccinations by age 24 months. Disparities in coverage were seen for race/ethnicity, poverty status, and health insurance status. Coverage with most vaccines was lower among children who were not privately insured. The largest disparities between insurance categories were among uninsured children, especially for ≥2 doses of influenza vaccine, the combined 7-vaccine series, § and rotavirus vaccination. Reported estimates reflect vaccination opportunities that mostly occurred before disruptions resulting from the COVID-19 pandemic. Extra efforts are needed to ensure that children who missed vaccinations, including those attributable to the COVID-19 pandemic, receive them as soon as possible to maintain protection against vaccine-preventable illnesses.
P49.01 Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC
Authors: S. Dong, Z. Wang, Q. Zhou, L. Yang, J. Zhang, Y. Chen, S. Liu, J. Lin, R. Liao, H. Tu, C. Xu, X. Yang, W. Zhong, J. Yang, Y. Wu
Journal: Journal of Thoracic Oncology (2021)
P54.04 Detecting Elevated Risk of Diminished Quality of Life Among Lung Cancer Patients by Using Wearable Devices
Authors: M. Torrente, F. Franco, A. Collazo Lorduy, V. Calvo, P. Martinez, C. Parejo, M. Campos, P. Alamaida-Pagan, B. Rodriguez-Morilla, M.A. Rol, J.A. Madrid, M.J. Martinez-Madrid, B. Cantos, C. Maximiano, M. Mendez, G. Visedo, S. Cristina, E. Menasalvas, P. Sousa, J. Pimentao, A. Morito, M. Provencio
Journal: Journal of Thoracic Oncology (2021)
A new semi-orthotopic bone defect model for cell and biomaterial testing in regenerative medicine
Authors: E. Andrés Sastre, Y. Nossin, I. Jansen, N. Kops, C. Intini, J. Witte-Bouma, B. van Rietbergen, S. Hofmann, Y. Ridwan, J.P. Gleeson, F.J. O'Brien, E.B. Wolvius, G.J.V.M. van Osch, E. Farrell
Journal: Biomaterials (2021)

In recent decades, an increasing number of tissue engineered bone grafts have been developed. However, expensive and laborious screenings in vivo are necessary to assess the safety and efficacy of their formulations. Rodents are the first choice for initial in vivo screens but their size limits the dimensions and number of the bone grafts that can be tested in orthotopic locations. Here, we report the development of a refined murine subcutaneous model for semi-orthotopic bone formation that allows the testing of up to four grafts per mouse one order of magnitude greater in volume than currently possible in mice. Crucially, these defects are also "critical size" and unable to heal within the timeframe of the study without intervention. The model is based on four bovine bone implants, ring-shaped, where the bone healing potential of distinct grafts can be evaluated in vivo. In this study we demonstrate that promotion and prevention of ossification can be assessed in our model. For this, we used a semi-automatic algorithm for longitudinal micro-CT image registration followed by histological analyses. Taken together, our data supports that this model is suitable as a platform for the real-time screening of bone formation, and provides the possibility to study bone resorption, osseointegration and vascularisation.
P28.02 Beyond PACIFIC: Outcomes and Toxicity According to Durvalumab Dosing Schedule Every 2 versus 4 Weeks
Authors: M. Denault, S. Kuang, A. Shokoohi, B. Leung, M. Liu, J. Laskin, T. Zhang, B. Melosky, C. Ho, E. Berthelet, S. Sun
Journal: Journal of Thoracic Oncology (2021)
Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509–2518
Authors: Julio Rosenstock
Journal: Diabetes Care (2021)

I thank Dr. Marathe and coauthors, who are part of the superb team of Michael Horowitz and Karen Jones, world-renowned top experts in gastric emptying (1), for recognizing the clinical value of our albiglutide switch study (HARMONY 8), which provided proof of concept for the benefits of using a weekly glucagon-like peptide 1 receptor agonist (GLP-1RA) to simplify an intensive multiple-insulin regimen in patients with long-standing type 2 diabetes previously on basal-bolus insulin (2). We clearly demonstrated that 54% of participants randomized to the albiglutide + basal insulin glargine group were able to replace all prandial insulin without reintroducing insulin lispro, and, for those who still needed prandial insulin, their insulin doses were substantially …
NHS staff face growing tide of abuse from patients frustrated by long waits for care
Authors: Elisabeth Mahase
Journal: BMJ (2021)

NHS staff are reporting an unprecedented rise in abuse from patients and the public, medical bodies have warned.1

In a joint statement from the BMA, the Academy of Medical Royal Colleges, NHS Employers, the Royal College of Nursing, and UNISON, leaders said that while patients are understandably frustrated by long waits and delays in the care they rightly expect, blaming members of …
Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval
Authors: Mahnum Shahzad, Huseyin Naci, Anita K. Wagner
Journal: JAMA Internal Medicine (2021)

Stacie B. Dusetzina, PhD; Ameet Sarpatwari, PhD, JD; Michael A. Carrier, JD; Richard A. Hansen, PhD; Nancy L. Keating, MD, MPH; Haiden A. Huskamp, PhD
The four weeks before lockdown during the COVID-19 pandemic in Germany: a weekly serial cross-sectional survey on risk perceptions, knowledge, public trust and behaviour, 3 to 25 March 2020
Authors: Cornelia Betsch, Lars Korn, Tanja Burgard, Wolfgang Gaissmaier, Lisa Felgendreff, Sarah Eitze, Philipp Sprengholz, Robert Böhm, Volker Stollorz, Michael Ramharter, Nikolai Promies, Freia De Bock, Philipp Schmid, Britta Renner, Lothar H Wieler, Michael Bosnjak
Journal: Eurosurveillance (2021)

Background During the COVID-19 pandemic, public perceptions and behaviours have had to adapt rapidly to new risk scenarios and radical behavioural restrictions. Aim To identify major drivers of acceptance of protective behaviours during the 4-week transition from virtually no COVID-19 cases to the nationwide lockdown in Germany (3–25 March 2020). Methods A serial cross-sectional online survey was administered weekly to ca 1,000 unique individuals for four data collection rounds in March 2020 using non-probability quota samples, representative of the German adult population between 18 and 74 years in terms of age × sex and federal state (n = 3,910). Acceptance of restrictions was regressed on sociodemographic variables, time and psychological variables, e.g. trust, risk perceptions, self-efficacy. Extraction of homogenous clusters was based on knowledge and behaviour. Results Acceptance of restrictive policies increased with participants’ age and employment in the healthcare sector; cognitive and particularly affective risk perceptions were further significant predictors. Acceptance increased over time, as trust in institutions became more relevant and trust in media became less relevant. The cluster analysis further indicated that having a higher education increased the gap between knowledge and behaviour. Trust in institutions was related to conversion of knowledge into action. Conclusion Identifying relevant principles that increase acceptance will remain crucial to the development of strategies that help adjust behaviour to control the pandemic, possibly for years to come. Based on our findings, we provide operational recommendations for health authorities regarding data collection, health communication and outreach.
Residency Program Director Perspectives on Changes to US Medical Licensing Examination
Authors: Andrew Wang, Krystal L. Karunungan, Jacob D. Story, Edward L. Ha, Clarence H. Braddock
Journal: JAMA Network Open (2021)

This survey study examines the perspectives of residency program directors regarding reporting the US Medical Licensing Examination (USMLE) Step 1 as pass/fail and discontinuing Step 2 Clinical Skills.
Cav1.4 calcium channels control cytokine production by human peripheral TH17 cells and psoriatic skin-infiltrating T cells
Authors: Marion Mars, Isabelle Néant, Catherine Leclerc, Stéphanie Bosch, Christian Rouviere, Marc Moreau, Simon Lachambre, Carle Paul, Marie Tauber, Eléonore Gravier, Clara Douzal, Hélène Duplan, Marine Babin, Alexia Brocario, Marie-Dominique Thouvenin, Jean-Charles Guéry, Daniel Redoules, Fabrice Lestienne, Lucette Pelletier, Magali Savignac
Journal: Journal of Allergy and Clinical Immunology (2021)
P38.02 The Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) In Lung Metastasectomy for Colorectal Cancer: A Meta-Analysis
Authors: D. Magouliotis, M. Fergadi, D. Koukousaki, E. Tatsios, T. Athanasiou
Journal: Journal of Thoracic Oncology (2021)
Effects of contrast-enhanced ultrasound treatment on neoadjuvant chemotherapy in breast cancer
Authors: Anne Rix, Marion Piepenbrock, Barbara Flege, Saskia von Stillfried, Patrick Koczera, Tatjana Opacic, Nina Simons, Peter Boor, Sven Thoröe-Boveleth, Roel Deckers, Jan-Niklas May, Twan Lammers, Georg Schmitz, Elmar Stickeler, Fabian Kiessling
Journal: Theranostics (2021)

Preclinical and clinical data indicate that contrast-enhanced ultrasound can enhance tumor perfusion and vessel permeability, thus, improving chemotherapy accumulation and therapeutic outcome. Therefore, we investigated the effects of high mechanical index (MI) contrast-enhanced Doppler ultrasound (CDUS) on tumor perfusion in breast cancer.
Impaired memory B-cell response to the Pfizer-BioNTech COVID-19 vaccine in patients with common variable immunodeficiency
Authors: Ane Fernandez Salinas, Eva Piano Mortari, Sara Terreri, Cinzia Milito, Salvatore Zaffina, Carlo Federico Perno, Franco Locatelli, Isabella Quinti, Rita Carsetti
Journal: Journal of Allergy and Clinical Immunology (2021)
Using Deep-Learning Algorithms to Simultaneously Identify Right and Left Ventricular Dysfunction From the Electrocardiogram
Authors: Akhil Vaid, Kipp W. Johnson, Marcus A. Badgeley, Sulaiman S. Somani, Mesude Bicak, Isotta Landi, Adam Russak, Shan Zhao, Matthew A. Levin, Robert S. Freeman, Alexander W. Charney, Atul Kukar, Bette Kim, Tatyana Danilov, Stamatios Lerakis, Edgar Argulian, Jagat Narula, Girish N. Nadkarni, Benjamin S. Glicksberg
Journal: JACC. Cardiovascular imaging (2021)

This study sought to develop DL models capable of comprehensively quantifying left and right ventricular dysfunction from ECG data in a large, diverse population. Rapid evaluation of left and right ventricular function using deep learning (DL) on electrocardiograms (ECGs) can assist diagnostic workflow. However, DL tools to estimate right ventricular (RV) function do not exist, whereas those to estimate left ventricular (LV) function are restricted to quantification of very low LV function only. A multicenter study was conducted with data from 5 New York City hospitals: 4 for internal testing and 1 serving as external validation. We created novel DL models to classify left ventricular ejection fraction (LVEF) into categories derived from the latest universal definition of heart failure, estimate LVEF through regression, and predict a composite outcome of either RV systolic dysfunction or RV dilation. We obtained echocardiogram LVEF estimates for 147,636 patients paired to 715,890 ECGs. We used natural language processing (NLP) to extract RV size and systolic function information from 404,502 echocardiogram reports paired to 761,510 ECGs for 148,227 patients. For LVEF classification in internal testing, area under curve (AUC) at detection of LVEF ≤40%, 40% < LVEF ≤50%, and LVEF >50% was 0.94 (95% CI: 0.94-0.94), 0.82 (95% CI: 0.81-0.83), and 0.89 (95% CI: 0.89-0.89), respectively. For external validation, these results were 0.94 (95% CI: 0.94-0.95), 0.73 (95% CI: 0.72-0.74), and 0.87 (95% CI: 0.87-0.88). For regression, the mean absolute error was 5.84% (95% CI: 5.82%-5.85%) for internal testing and 6.14% (95% CI: 6.13%-6.16%) in external validation. For prediction of the composite RV outcome, AUC was 0.84 (95% CI: 0.84-0.84) in both internal testing and external validation. DL on ECG data can be used to create inexpensive screening, diagnostic, and predictive tools for both LV and RV dysfunction. Such tools may bridge the applicability of ECGs and echocardiography and enable prioritization of patients for further interventions for either sided failure progressing to biventricular disease.
FP06.03 COVID-19: Does Thoracic Surgery Increase Mortality Rates during the Pandemic?
Authors: M.T. Tsukazan, L. Bittencourt Hinrichsen, G.F. Schneider, P.A. Schulze, M. Iglesias, A. Vigo, R. Paulino, T. Menegaz, B. Mana, K. Klein, J. Rios, A. Schneider, J. Figueiredo Pinto
Journal: Journal of Thoracic Oncology (2021)
Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain
Authors: Megan S. Keiser, Paul T. Ranum, Carolyn M. Yrigollen, Ellie M. Carrell, Geary R. Smith, Amy L. Muehlmatt, Yong Hong Chen, Joel M. Stein, Ronald L. Wolf, Enrico Radaelli, Timothy J. Lucas, Pedro Gonzalez-Alegre, Beverly L. Davidson
Journal: Nature Medicine (2021)
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma
Authors: Hannah M. Knochelmann, Joshua D. Horton, Sixue Liu, Kent Armeson, John M. Kaczmar, Megan M. Wyatt, Mary S. Richardson, Shirley H. Lomeli, Ying Xiong, Evan M. Graboyes, Eric J. Lentsch, Joshua D. Hornig, Judith Skoner, Seth Stalcup, Maria V. Spampinato, Elizabeth Garrett-Mayer, Elizabeth C. O’Quinn, Cynthia D. Timmers, Martin J. Romeo, John M. Wrangle, M. Rita I. Young, Mark P. Rubinstein, Terry A. Day, Roger S. Lo, Chrystal M. Paulos, David M. Neskey
Journal: Cell Reports Medicine (2021)

Oral cavity squamous cell carcinoma (OCSCC) is a prevalent surgically treated subset of head and neck cancer with frequent recurrence and poor survival. Immunotherapy has demonstrated efficacy in recurrent/metastatic head and neck cancer. However, whether antitumor responses could be fostered by neoadjuvant presurgical immunotherapy remains unclear. Using a Simon's two-stage design, we present results of a single-arm phase-II trial where 12 patients with stage II-IVA OCSCC received 3 to 4 biweekly doses of 3 mg/kg nivolumab followed by definitive surgical resection with curative intent. Presurgical nivolumab therapy in this cohort shows an overall response rate of 33% (n = 4 patients; 95% CI: 12%–53%). With a median follow up of 2.23 years, 10 out of 12 treated patients remain alive. Neoadjuvant nivolumab is safe, well-tolerated, and is not associated with delays in definitive surgical treatment in this study. This work demonstrates feasibility and safety for incorporation of nivolumab in the neoadjuvant setting for OCSCC (ClinicalTrials.gov: NCT03021993).
Early Impedance-Guided Intervention Improves Long-Term Outcome in Patients With Heart Failure
Authors: Michael Kleiner Shochat, Marat Fudim, Daniel Kapustin, Mark Kazatsker, Ilia Kleiner, Jean Marc Weinstein, Gurusher Panjrath, Guy Rozen, Ariel Roguin, Simcha R. Meisel
Journal: Journal of the American College of Cardiology (2021)
Metabolic remodelling during early mouse embryo development
Authors: Jing Zhao, Ke Yao, Hua Yu, Ling Zhang, Yuyan Xu, Lang Chen, Zhen Sun, Yuqing Zhu, Cheng Zhang, Yuli Qian, Shuyan Ji, Hongru Pan, Min Zhang, Jie Chen, Cristina Correia, Taylor Weiskittel, Da-Wei Lin, Yuzheng Zhao, Sriram Chandrasekaran, Xudong Fu, Dan Zhang, Heng-Yu Fan, Wei Xie, Hu Li, Zeping Hu, Jin Zhang
Journal: Nature Metabolism (2021)
Seeing more with less: virtual gadolinium-enhanced glioma imaging
Authors: Alexandros Ferles, Frederik Barkhof
Journal: The Lancet Digital Health (2021)

MRI is the main modality to diagnose and monitor the evolution and treatment of brain tumours. Radiological tumour grading relies on evidence of abnormal blood–brain barrier permeability, achieved by intravenous injection of gadolinium-based contrast agents (GBCA), leading to enhanced signal intensity on T1-weighted images. The current goal in glioma surgery is resection of the enhancing tumour parts and the response assessment in neuro-oncology (RANO) criteria for monitoring glioma treatment response heavily rely on the demonstration of recurring or enlarging enhancing tumour.
P31.01 Impact of COVID-19 on Lung Cancer Diagnosis and Treatment: A Retrospective Chart Review
Authors: G. Kasymjanova, A. Anwar, L. Sakr, V. Cohen, D. Small, H. Wang, K. Sultanem, C. Pepe, J. Friedmann, J. Agulnik
Journal: Journal of Thoracic Oncology (2021)
Abstract 1500: Efficacy and Safety of the MTP-inhibitor, AEGR-733, as Monotherapy and in Combination with Ezetimibe
Authors: Frederick F Samaha, James McKenney, LeAnne T Bloedon, William J Sasiela, Daniel J Rader
Journal: Circulation (2006)

Numerous studies have demonstrated the critical importance of lowering LDL-C on the reduction in CV events. While statin therapy remains the foundation of such treatment, not all patients can achie...
Tumour Treating Fields in Glioblastoma: Is the treatment tolerable, effective, and practical in UK Patients?
Authors: Farouk Olubajo, Antonia Thorpe, Charles Davis, Anna Crofton, Samantha J Mills, Michael Jenkisnon, Colin Watts, Stephen Price, Andrew Brodbelt
Journal: Neuro-Oncology (2021)

Abstract Aims Tumour Treating Fields (TTF) in combination with standard therapy, prolongs survival in patients with Glioblastoma (GBM). The aim of the current study was to assess the feasibility of integrating TTF into a standard UK neuro-oncology service with a focus on patient tolerability, compliance, and treatment delivery. Method A prospective study was performed of UK patients with IDH 1 Wild Type, MGMT Unmethylated GBM treated with TTF, in conjunction with conventional therapy. Patient compliance data, device-specific tolerability questions, and an evaluation of disease progression and survival were collected. Monthly quality of life (QoL) questionnaires (EORTC QLQ-C30 with BN-20) examined the trend of global health, psychosocial function and symptom progression. Results Nine patients were enrolled with a median age of 47 (7 males; 2 females). Overall, compliance with TTF was 89% (range 16% - 97%). Only one patient failed to comply with treatment. Patients tolerated the device with minimal side effects. Eight patients described mild to moderate skin irritation, whilst all patients were keen to recommend the device to other patients (100%). Most patients found the weight and size of the device to be its biggest drawback (72%). Progression-free survival was 5.5 months and median overall survival 14.9 months. Conclusion TTF was well tolerated amongst a small cohort of UK patients, who were able to comply with treatment without any significant complication. QoL questionnaires showed no sustained deterioration in global health, physical and emotional function until the final months of life, when disease burden was greatest.
MA07.06 Circulating Tumor DNA for Monitoring Minimal Residual Disease and Early Detection of Recurrence in Early Stage Lung Cancer
Authors: A. Tan, G. Lai, S. Saw, K. Chua, A. Takano, B. Ong, T. Koh, A. Jain, W. Tan, Q. Ng, R. Kanesvaran, T. Rajasekaran, E. Kalshnikova, S. Shchegrova, None H. -Ta, J. Lin, D. Renner, H. Sethi, B. Zimmermann, A. Aleshin, W. Lim, E. Tan, A. Skanderup, M. Ang, D. Tan
Journal: Journal of Thoracic Oncology (2021)